AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 287: H2412-H2420, 2004. First published July 29, 2004; doi:10.1152/ajpheart.00527.2004
0363-6135/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/6/H2412    most recent
00527.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, X.
Right arrow Articles by Spector, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, X.
Right arrow Articles by Spector, A. A.

Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels

Xiang Fang,1 Neal L. Weintraub,2,3,4 Ryan B. McCaw,1 Shanming Hu,1 Shawn D. Harmon,1 James B. Rice,2 Bruce D. Hammock,5 and Arthur A. Spector1,2

Departments of 1Biochemistry, 2Internal Medicine, and 3Radiation Oncology, Carver College of Medicine, University of Iowa, Iowa City 52242; 4Veterans Administration Medical Center, Iowa City, Iowa 52242; and 5Department of Entomology and Cancer Research Center, University of California, Davis, California 95616

Submitted 7 June 2004 ; accepted in final form 27 July 2004

We investigated the effects of soluble epoxide hydrolase (sEH) inhibition on epoxyeicosatrienoic acid (EET) metabolism in intact human blood vessels, including the human saphenous vein (HSV), coronary artery (HCA), and aorta (HA). When HSV segments were perfused with 2 µmol/l 14,15-[3H]EET for 4 h, >60% of radioactivity in the perfusion medium was converted to 14,15-dihydroxyeicosatrienoic acid (DHET). Similar results were obtained with endothelium-denuded vessels. 14,15-DHET was released from both the luminal and adventitial surfaces of the HSV. When HSVs were incubated with 14,15-[3H]EET under static (no flow) conditions, formation of 14,15-DHET was detected within 15 min and was inhibited by the selective sEH inhibitors N,N'-dicyclohexyl urea and N-cyclohexyl-N'-dodecanoic acid urea (CUDA). Similarly, CUDA inhibited the conversion of 11,12-[3H]EET to 11,12-DHET by the HSV. sEH inhibition enhanced the uptake of 14,15-[3H]EET and facilitated the formation of 10,11-epoxy-16:2, a {beta}-oxidation product. The HCA and HA converted 14,15-[3H]EET to DHET, and this also was inhibited by CUDA. These findings in intact human blood vessels indicate that conversion to DHET is the predominant pathway for 11,12- and 14,15-EET metabolism and that sEH inhibition can modulate EET metabolism in vascular tissue.

dihydroxyeicosatrienoic acids; cytochrome P-450; saphenous vein; {beta}-oxidation


Address for reprint requests and other correspondence: X. Fang, Dept. of Biochemistry, 4-403 BSB, Univ. of Iowa College of Medicine, Iowa City, IA 52242 (E-mail: xiang-fang{at}uiowa.edu)




This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
K. R. Chaudhary, S. N. Batchu, D. Das, M. R. Suresh, J. R. Falck, J. P. Graves, D. C. Zeldin, and J. M. Seubert
Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function
Cardiovasc Res, July 15, 2009; 83(2): 362 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Motoki, M. J. Merkel, W. H. Packwood, Z. Cao, L. Liu, J. Iliff, N. J. Alkayed, and D. M. Van Winkle
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2128 - H2134.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. J. Corenblum, V. E. Wise, K. Georgi, B. D. Hammock, P. A. Doris, and M. Fornage
Altered Soluble Epoxide Hydrolase Gene Expression and Function and Vascular Disease Risk in the Stroke-Prone Spontaneously Hypertensive Rat
Hypertension, February 1, 2008; 51(2): 567 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
B. T. Larsen, D. D. Gutterman, A. Sato, K. Toyama, W. B. Campbell, D. C. Zeldin, V. L. Manthati, J. R. Falck, and H. Miura
Hydrogen Peroxide Inhibits Cytochrome P450 Epoxygenases: Interaction Between Two Endothelium-Derived Hyperpolarizing Factors
Circ. Res., January 4, 2008; 102(1): 59 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. A. Spector and A. W. Norris
Action of epoxyeicosatrienoic acids on cellular function
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Fang, F. M. Faraci, T. L. Kaduce, S. Harmon, M. L. Modrick, S. Hu, S. A. Moore, J. R. Falck, N. L. Weintraub, and A. A. Spector
20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: role of cyclooxygenase
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2301 - H2307.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. M. Seubert, C. J. Sinal, J. Graves, L. M. DeGraff, J. A. Bradbury, C. R. Lee, K. Goralski, M. A. Carey, A. Luria, J. W. Newman, et al.
Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function
Circ. Res., August 18, 2006; 99(4): 442 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. R. Lee, K. E. North, M. S. Bray, M. Fornage, J. M. Seubert, J. W. Newman, B. D. Hammock, D. J. Couper, G. Heiss, and D. C. Zeldin
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study
Hum. Mol. Genet., May 15, 2006; 15(10): 1640 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
B. T. Larsen, H. Miura, O. A. Hatoum, W. B. Campbell, B. D. Hammock, D. C. Zeldin, J. R. Falck, and D. D. Gutterman
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H491 - H499.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Fang, S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al.
14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-{alpha}
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H55 - H63.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Vriens, G. Owsianik, B. Fisslthaler, M. Suzuki, A. Janssens, T. Voets, C. Morisseau, B.D. Hammock, I. Fleming, R. Busse, et al.
Modulation of the Ca2 Permeable Cation Channel TRPV4 by Cytochrome P450 Epoxygenases in Vascular Endothelium
Circ. Res., October 28, 2005; 97(9): 908 - 915.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
O. Jung, R. P. Brandes, I.-H. Kim, F. Schweda, R. Schmidt, B. D. Hammock, R. Busse, and I. Fleming
Soluble Epoxide Hydrolase Is a Main Effector of Angiotensin II-Induced Hypertension
Hypertension, April 1, 2005; 45(4): 759 - 765.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.